BrainStorm Cell Limited


Brainstorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the FDA and the EMA for the treatment of amyotrophic lateral sclerosis (ALS).


Founded 2004
Type Public
Location New York, New York, USA


BCLI $4.17 -0.24% $(0.01)

Latest News

22 Stocks Moving in Monday's Pre-Market Session Jun 07, 2021 Benzinga Gainers Liminal BioSciences Inc. (NASDAQ: LMNL) rose 51.7% to $6.10 in pre-market trading. Liminal BioSciences reported the FDA approval for its Biologics License Application for...
Earnings Scheduled For April 26, 2021 Apr 26, 2021 Benzinga Companies Reporting Before The Bell • Albertsons Companies (NYSE:ACI) is projected to report quarterly earnings at $0.51 per share on revenue of $15.63 billion. •...